Lynch syndrome is an inherited genetic condition that significantly raises your lifetime risk of developing several types of cancer, most notably colorectal and endometrial cancer. It affects roughly 1 in 300 to 1 in 500 people, though most don’t know they carry it. The condition accounts for 2 to 3% of all colorectal cancer cases and is caused by mutations in genes responsible for repairing everyday errors in your DNA.
How Lynch Syndrome Causes Cancer
Every time your cells divide, they copy billions of DNA letters. Mistakes happen during this copying process, and your body has a built-in proofreading system to catch and fix those errors. In Lynch syndrome, one of the genes that runs this proofreading system is broken. The five genes involved are MLH1, MSH2, MSH6, PMS2, and PMS1. When any of these genes don’t work properly, small DNA errors accumulate over time, particularly in stretches of repetitive DNA called microsatellites. This buildup of uncorrected mutations drives cells toward cancer far more quickly than in people with functioning repair genes.
This is why cancers in Lynch syndrome tend to develop at younger ages. The normal process of cancer development, which might take decades in someone with intact DNA repair, is accelerated when the proofreading system can’t keep up.
Lifetime Cancer Risks
Colorectal cancer is the hallmark risk. Men with Lynch syndrome face a lifetime colorectal cancer risk of roughly 65 to 80%, depending on which gene is affected. Women’s colorectal cancer risk ranges from about 40 to 60%. For comparison, the average person’s lifetime risk of colorectal cancer is around 4 to 5%.
Endometrial cancer is the second major concern and affects women at strikingly high rates. Women with MLH1 or MSH2 mutations have an estimated 40 to 60% lifetime risk of endometrial cancer. Women with MSH6 mutations face an even higher risk: up to 71% by age 70.
Beyond these two primary cancers, Lynch syndrome raises the risk of a broader range of malignancies. Gastric cancer was historically recognized as the third most common Lynch-associated cancer. Ovarian cancer, cancers of the upper urinary tract (ureter and renal pelvis), small bowel cancer, pancreatic and bile duct cancers, and certain brain tumors all occur more frequently in people with Lynch syndrome than in the general population. A specific skin-related variant called Muir-Torre syndrome involves sebaceous skin tumors alongside internal cancers. Some studies have also identified higher rates of certain blood cancers, including leukemia and non-Hodgkin’s lymphoma, in Lynch syndrome families.
How It’s Inherited
Lynch syndrome follows an autosomal dominant inheritance pattern. That means you only need one copy of the faulty gene (from one parent) to have the condition. If one of your parents carries the mutation, you have a 50% chance of inheriting it. Each of your children, in turn, has the same 50% chance.
It’s worth noting that inheriting the mutation doesn’t guarantee you’ll develop cancer. It means your risk is substantially elevated compared to someone without the mutation. The condition has about 85% penetrance, meaning the large majority of carriers will develop at least one associated cancer during their lifetime if no preventive measures are taken.
How Lynch Syndrome Is Identified
There are two main paths to a Lynch syndrome diagnosis: family history criteria and tumor testing.
Doctors have long used clinical criteria to flag families who might carry the syndrome. The Amsterdam II criteria, established in 1999, look for at least three relatives with a Lynch-associated cancer (colorectal, endometrial, small bowel, ureter, or renal pelvis), spanning at least two generations, with at least one case diagnosed before age 50, and at least one person being a first-degree relative of the other two. These criteria are highly specific but miss many carriers, particularly people from smaller families or those without a strong known family history.
The Bethesda criteria cast a wider net. They flag individuals for further testing based on factors like being diagnosed with colorectal or endometrial cancer before age 45, having multiple Lynch-associated cancers, or having colorectal cancer with specific microscopic features.
Many hospitals now perform universal screening on all colorectal tumor samples. This involves two lab techniques: immunohistochemistry (IHC), which checks whether the four main repair proteins are present in the tumor, and microsatellite instability (MSI) testing, which looks for the pattern of DNA errors characteristic of faulty repair. If IHC shows a missing protein or MSI testing is positive, the next step is usually a blood or saliva test to look for an inherited mutation in the corresponding gene. This genetic (germline) test is what confirms a Lynch syndrome diagnosis. The distinction matters: tumor screening can flag a potential problem, but only germline testing tells you whether the condition is inherited and can be passed to your children.
Screening and Surveillance
Regular colonoscopies are the cornerstone of cancer prevention for people with Lynch syndrome, because catching polyps or early cancers dramatically improves outcomes. For carriers of MLH1 or MSH2 mutations, guidelines recommend starting colonoscopies between ages 20 and 25, repeated every one to two years. For MSH6 and PMS2 carriers, whose cancer risks tend to emerge later, screening can often begin at age 30 to 35, with intervals of every one to three years depending on the gene involved.
Women with Lynch syndrome are typically offered additional surveillance for endometrial and ovarian cancer, though screening for these cancers is less straightforward than colonoscopy. Options may include regular pelvic ultrasounds or endometrial sampling, though the evidence for their effectiveness is less robust than for colonoscopy.
Reducing Cancer Risk
Daily Aspirin
Daily aspirin has emerged as a meaningful tool for reducing colorectal cancer risk in Lynch syndrome carriers. The landmark CAPP2 trial showed that taking aspirin reduced colorectal cancer incidence in people with the condition. The original trial used 600 mg per day, but most current international guidelines recommend a lower dose of 75 to 100 mg daily, taken for a minimum of two years. Some guidelines suggest higher doses for people who are overweight. A follow-up trial (CAPP3) is currently evaluating the optimal dose, but many medical organizations already recommend that carriers start low-dose aspirin without waiting for those results.
Preventive Surgery
For women with Lynch syndrome who have completed childbearing, preventive removal of the uterus and ovaries (hysterectomy with bilateral salpingo-oophorectomy) is an effective strategy for eliminating the risk of endometrial and ovarian cancer. Research published in the New England Journal of Medicine found that this approach effectively prevented both cancers in women with the syndrome. The decision is a personal one that weighs cancer risk against the effects of surgical menopause and is typically discussed in detail with a genetic counselor and gynecologic oncologist.
Why Many Carriers Don’t Know
Despite affecting as many as 1 in 300 people, Lynch syndrome remains significantly underdiagnosed. Many carriers have no idea they’re at elevated risk until they or a family member are diagnosed with cancer. This is partly because the condition doesn’t cause symptoms on its own, and partly because family history can be incomplete or misleading. Small family size, adoption, early deaths from other causes, or simply not knowing a relative’s medical details can all obscure the pattern. Universal tumor screening programs, now adopted at many medical centers, are catching cases that family history alone would miss. When one person in a family is identified, genetic testing of blood relatives can identify other carriers before cancer develops, turning a reactive diagnosis into a proactive one.